Aldeyra療法 ALDX 深 滬
已收盤 08-22 16:00:00 美东时间
5.81
-0.070
-1.19%
華盛通- 最 高6.05
- 今 開5.89
- 成交量 102.65万股
- 最 低 5.66
- 昨 收 5.88
- 總市值 3.48亿
- 52周最高 7.20
- 市盈率 靜 --
- 換手率 1.71%
- 52周最低 1.14
- 委 比 -77.52%
- 總股本 5989.56万
- 歷史最高 16.70
- 量 比 1.22
- 振 幅 6.63%
- 歷史最低 1.14
- 每 手 1
- 風險率 1.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the
08-19 19:05
Aldeyra says FDA accepted resubmitted marketing application for lead drug
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that the U.S. Food and Drug Administration (FDA) accepted for review its resubmitted New Drug Application (NDA) for its lead drug reproxalap, t...
07-17 19:42
FDA Accepts Aldeyra’s Reproxalap Application for Review
Aldeyra Therapeutics ( ($ALDX) ) has provided an update. On July 17, 2025, Alde...
07-17 19:27
Aldeyra resubmits Reproxalap's marketing application to FDA
Aldeyra Therapeutics (NASDAQ:ALDX) said that it has resubmitted its marketing application to the U.S. FDA for its dry eye treatment, reproxalap. According to the FDA, the resubmission includes only ne...
06-17 22:39
Aldeyra Resubmits Reproxalap NDA to FDA
An update from Aldeyra Therapeutics ( ($ALDX) ) is now available. On June 17, 2...
06-17 19:29
Aldeyra Resubmits Eye Drug for FDA Review After New Trial Clears Key Hurdle in Treating Dry Eye
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the
06-17 19:03
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
05-30 01:28
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
05-19 18:36
Aldeyra Therapeutics Appoints Chip Clark to Board
Aldeyra Therapeutics ( ($ALDX) ) has issued an announcement. On April 17, 2025,...
04-18 04:33
